NCT06981390Not yet recruiting
Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG
Ticagrelor-Based Dual Antiplatelet Therapy in Coronary Artery Bypass Grafting: A Randomized Clinical Trial on Graft Patency
Source: ClinicalTrials.gov · Last updated 24 Apr 2026
Brief summary (registry, in English)
This randomized controlled trial aims to evaluate the impact of different durations of Ticagrelor-based dual antiplatelet therapy (DAPT) on saphenous vein graft (SVG) patency in patients undergoing coronary artery bypass grafting (CABG). A total of 300 patients will be randomly assigned to receive Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 3 months, 6 months, or 12 months, followed by aspirin monotherapy.The primary outcome is 1-year graft patency, assessed via coronary CT angiography. Secondary outcomes include bleeding events (BARC classification), major adverse cardiovascular and cerebrovascular events (MACCE), and all-cause mortality. The study aims to determine the optimal DAPT duration to balance graft patency benefits and bleeding risks, ultimately guiding postoperative antiplatelet strategies for CABG patients.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 2 May 2025
- Start date
- 1 May 2026
- Primary completion date
- 20 Feb 2027
- Lead sponsor
- Kexiang Liu, MD
- Diseases
- Coronary artery disease
- NCT number
- NCT06981390
What you commit to
- Study type: Interventional
- Planned participants: 300
- From 1 May 2026 to the primary completion date, 20 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients undergoing concomitant valve surgery (excluding aortic bioprosthesis), aortic surgery, or rhythm surgery during the same session.
- Patients requiring antiplatelet therapy other than aspirin or ticagrelor (e.g., clopidogrel, prasugrel) and unable to discontinue such medication after CABG, based on physician or investigator judgment.
- Patients on oral anticoagulants before CABG who must continue anticoagulation therapy postoperatively.
- Patients with a drug-eluting stent (DES) in a coronary or cerebral artery within 6 months before CABG, or a bare-metal stent (BMS) within 1 month before CABG.
- Patients using strong CYP3A4 inhibitors.
- Patients requiring methotrexate and ibuprofen therapy.
Other illness
- Patients with single-vessel coronary artery disease.
- Patients with sick sinus syndrome, second- or third-degree atrioventricular block.
- Patients with contraindications for coronary computed tomography angiography (CCTA) or coronary angiography, including contrast media allergy.
- Patients with contraindications for ticagrelor or aspirin, including:
- 9.1Bleeding diathesis within the past 3 months. 9.2Severe gastrointestinal bleeding within the past year. 9.3Peptic ulcer (even without bleeding) within the past 3 years. 9.4History of intracranial hemorrhage, aspirin allergy, or severe aspirin-induced gastrointestinal reaction.
- Patients with active malignant tumors with an increased risk of bleeding, as determined by the investigator.
Lab values
- Patients with severe renal dysfunction requiring dialysis or active liver disease, including unexplained persistent transaminase elevation or transaminase levels \>3× the upper normal limit.
Other
- Patients undergoing emergency CABG.
- Patients with cardiogenic shock or hemodynamic instability.
- Patients with thrombocytopenia (\<100 x 10⁹/L) before CABG.
- Pregnant or breastfeeding women, and those who have given birth within the past 90 days.
- Premenopausal women not using adequate contraception. Adequate contraception requires at least two reliable methods, including one barrier method.
Who the study is looking for
- Patients 18-80 of age.
- Patients undergo planned CABG for the first time with ≥1 SVGs
- Patients with written informed consent.
Age in the registry: 18 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Second Hospital of Jilin University Coordinator of this site? Confirm its status | Changchun | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.